showed that intake of l -carnitine in various doses of 25, 50 and 100 mg/kg caused a decrease in serum total cholesterol, triglycerides, LDL (low-density lipoproteins) and HDL (high-density lipoproteins) cholesterol levels in experimental rats. (1 g twice daily) for 6 monthsBMI?, SBP?, DBP?, fasting glucose, postprandial blood glucose, HbA1c, insulin, HOMA-IR, IRAPe, TNF-, Visfatin, TC, TG, HDL, LDLEl-sheikh, El-Haggar and Elbedewy l-carnitine= 47) were randomly assigned to the placebo (= 24) and l-carnitine (= 23) groups.1000 mg l-carnitine/d (2 500 mg capsules) for 12 weeks? CRP, IL-6, TNF-;= 47) were randomly assigned to the placebo (= 24) and L-carnitine (= 23) groups.1000 mg l-carnitine/d (2 500 mg capsules) for 12 weeks? CAT, GPx, SOD, MDA, l-carnitine= 75) who treated with oral antidiabetic drugs metformin and sulfonylurea) were randomly assigned into l-carnitine, coenzyme Q10 and control groups.l-carnitine 1000 mg tablet once daily for 8 weeksglucose, HbA1c?, TC, LDL, HDL?, Lp(a)Mohammed-Jawad et al. 150 mg coenzyme Q10 soft gel daily (2 75 mg) for 8 weeksglucose, HbA1c, TC, LDL, HDL?, Lp(a)l-carnitine= 30) were randomly allocated into l-carnitine (= 15) and control (= 15) groups4 g l-carnitine infusion daily (2 g twice a day) for 7 days? BW, BMI, WC, HC, WHR, SBP?, DBP?, TC?,TG, HDL, LDL, ApoA1, ApoB, ApoA1/ ApoB, Lp(a), glucose, insulin, HOMA-IR, CRP?, UA, FFA, AST, ALT?, GGT 0.001), mental fatigue (l-carnitine vs. control, = 0.001), and fatigue severity (l-carnitine vs. control, 0.001).Zhang et al. Carnosine= 30), were assigned to carnosine and placebo groups2 g/day (2 1 g) for 12 weeksadipsin?, leptin?, resistinBaye et al. l-Carnosine= 90) with type 1 diabetes, aged 9 to 18 years with at least 5 years disease duration, active diabetic nephropathy in the form of microalbuminuria were randomly assigned into carnosine (= 45), or matching placeb TNFRSF10D group (= 45). Patients in both Tolvaptan groups received oral captopril 25 mg tablet1 g/d (2 500 mg capsule) administered orally for 3 monthsBW?, BMI?, SBP?, DBP?, glucose?, TG, TC, HDL, HbA1c, creatinine?, UACR, Alpha 1-microglobulin, TAC, MDA, serum carnosineElbarbary et al. l-Carnosine= 54) were randomly assigned into carnosine (= 27) and placebo (= 27) group1 g/d (2 500 mg capsules) after a meal for 12 weeksBW?, BMI?, WC?, BFM, FFM, SBP, DBP?, glucose, HbA1c, insulin, HOMA-IR?, HOMA-?, TG, TC?, LDL?, HDL?, CML, pentosidine, s-RAGE?, TNF-, IL-6, IL-1?Houjeghani, Kheirouri, Faraji and Jafarabadi l-Carnosine= 54) were randomly assigned into carnosine (= 27) and placebo (= 27) group1 g/d (2 500 mg capsules) after a meal for 12 weeksglucose, CAT, SOD?, MDA, PCHoujeghani, Kheirouri, Faraji et al. Coenzyme Q10= 30) or placebo (= 30) groups120 mg coenzyme Q10/d (60 mg twice a day) for 12 weeksTAC, GSH?, MDA?, CRP, NOFallah, Askari, Soleimani et al. Coenzyme Q10= 101) were randomly assigned to the placebo (= 50) or coenzyme Q10 (= 51) groups.120 mg coenzyme Q10 daily (2 softgels 30 mg coenzyme Q10 each twice a day) for 24 weeksBW?, HC, WC?, BMI, SBP, DBP, TC?, TG, LDL, HDL?, non HDL?, ApoA1, ApoB?, ApoA1/ApoB, glucose, insulin, HOMA-IR, CRP?, TAC, AST?, ALT?, GGT?, urea?, creatinine?, UA?Zhang, Yang, Guoet al. Coenzyme Q10= 51) were randomly assigned to the placebo (= 24) or coenzyme Q10 (= 27) groups.300 mg coenzyme Q10/d for 12 weekscoenzyme Q10, vitamin E, SOD, CAT, GPx, CRP?, TNF-, IL-6?, adiponectin?Lee, Tseng, Yen and Lin Conjugated linoleic acid= 59), CLA-FFA (= 61) or CLA-triacylglycerol (= 60)4.5 g 80% CLA-FFA (3.6 g active CLA isomers) or 4.5 g 76% CLA triacylglycerols (3.4 g active isomers) for 12 monthsBW, BMI, BFM, LBM, BMM, diet daily intake, HbA1c, glucose?, TG?, TC?, HDL, LDL, Lp(a), leukocytes, thrombocytes, ALT?, ASTGaullier, Halse, H?ye et al. Conjugated linoleic acid= 45) assigned to placebo (= 23) or Tolvaptan CLA (= 22) groupsFour capsules daily for two weeks, crossing over to the other treatment arm after a wash-out of at least four weeks. The dose (4 g/day) provided 2.5 Tolvaptan g/day 9c,11t-CLA or 1.1% of energy? plasma FA: 16:0?, 18:0?, 18:1 t11?, 18:1 c9?, 18:2 n6?, 9c,11t-CLA, 10t,12c-CLA, 9c,11t+10t,12c-CLA, 18:3 n3?, 18:3 n6?, 20:3 n6?, 20:4 n6?, 20:5 n3?, 22:6 n3?Bachmair, Wood, Keizer et al. Conjugated linoleic acid (Tonalin? WDP 60)= 18), were randomly assigned to CLA (= 9) and (= 9) placebo groups3 g CLA 3 times dailyfor 30 daysWC?, HC?, BFM?, LMB?, BMI?, VO2 peak?, TC?, TG, VLDL, LDL, HDL?, ApoA?, ApoB?, ApoB/ApoA?, leptin, glucose?, insulin, HOMA-IR?, BChE, lipoprotein lipaseBulut, Bodur, Colak and Turnagol Conjugated linoleic acid= 14) assigned to placebo (= 7) or glutathione (= 7) groups3 g CLA/day added to strawberry jam for 90 daysglucose?,.